A B S T R A C T The present studies were performed in an effort to examine the characteristics of the control system governing phosphate excretion in uremic man. In a group of patients with glomerular filtration rates (GFR) ranging from normal to 2 ml/min, it was found that the lower the GFR the lower the fraction of filtered phosphate reabsorbed (TRP). On a fixed phosphate intake, phosphate excretion rate was the same in patients with GFRs ranging from 60 to 3 ml/min. When plasma phosphate concentrations were diminished to subnormal levels in hyperphosphatemic, hypocalcemic uremic patients, TRP values increased but did not return to normal. TRP failed to rise substantially when GFR, as well as plasma phosphate concentrations, were diminished. In patients with unilateral renal disease, TRP values were equal bilaterally, and values were substantially higher in the diseased kidneys than in patients with bilateral involvement. When plasma calcium concentrations were raised to normal for 2-3 wk in uremic patients in whom plasma phosphate concentrations had previously been lowered to subnormal levels, TRP values rose to an average value of 86%o. Values remained in the normal range when phosphate concentrations were allowed to increase while normocalcemia was maintained. The data are interpreted to indicate that in advancing renal disease, the changing patterns of phosphate excretion are mediated by a control system in which parathyroid hormone serves as a
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INTRODUCTION
The maintenance of phosphate balance in health and on a normal diet requires that each nephron excrete only a small fraction of its filtered phosphate. In progressive renal disease, with a reduction in the number of functioning nephrons, similar rates of total daily phosphate excretion in the urine can only be maintained by an increased rate of phosphate excretion per nephron. We previously have presented evidence that in uremic dogs high rates of phosphate excretion per nephron are mediated in major part by increased parathyroid hormone activity (1) . To date, however, efforts to distinguish between the role of parathyroid hormone, intrinsic disease of nephrons, and other factors in the phosphaturia observed in patients with chronic renal disease have not been uniformly successful. The present studies were undertaken therefore to examine the mechanisms which control the excretion of phosphate in uremic man.
METHODS
A total of 90 studies was performed in 24 patients with chronic progressive renal insufficiency. 13 patients had chronic glomerulonephritis, eight chronic pyelonephritis, and three polycystic renal disease.
All patients ingested a diet containing between 500 and 700 mg of phosphate per day. Control observations consisting of three to four consecutive clearance periods were obtained in each patient to establish the relationship between phosphate clearance and glomerular filtration rate (GFR). In the uremic patients, the control studies thus were performed without modifying either the hyper-phosphatemia or hypocalcemia. A number of special studies also were performed in which the experimental conditions were altered in one or more ways.
Controlled phosphate intake. In four patients representing a wide range of GFRs, a special diet was employed to maintain phosphate intake at 650 ± 50 mg/day. Studies were performed after this regimen had been in effect for at least 5 days.
Divided function studies. Two patients with unilateral pyelonephritis underwent split-function studies, and urine was collected separately from the two kidneys by the use of ureteral catheters.
Reduction in plasma phosphate concentrations. Plasma phosphate levels were reduced to subnormal levels in five hyperphosphatemic uremic patients by the chronic administration of a low phosphate diet together with oral aluminum carbonate gel,1 in a dose of 40-60 ml four times per day. The initial phosphate concentrations in these patients ranged from 6.5 to 10.0 mg/100 ml (mean 8.3 mg/100 ml); the final concentrations ranged from 1.4 to 3.6 mg/100 ml (mean 2.4 mg/100 ml). The time required to reduce the plasma concentrations varied from 12 to 20 days.
Elevation of plasma calcium concentrations in the presence of low plasma phosphate concentrations. In six hypocalcemic patients in whom plasma phosphate levels had been reduced to subnormal levels in the manner described above, plasma calcium concentrations were raised to a range of 9.1-11.5 mg/100 ml (mean 9.9 mg/ 100 ml) by the administration of 2-4 g of calcium gluconate four times daily and 200,000-300,000 U of vitamin D daily. Plasma calcium concentrations were followed very closely to prevent the occurrence of progressive hypercalcemia. Studies were performed after the calcium concentration had been in a normal range for 2-3 wk, and results were compared with control studies. Elevation of plasma phosphate concentrations to normal while normal plasma calcium concentrations were maintained. In three hypophosphatemic, normocalcemic patients receiving vitamin D and calcium, plasma phosphate levels were allowed to increase to normal by diminishing the dose of aluminum carbonate gel. Calcium concentrations were maintained within a normal range. Studies were performed before and after the restoration of phosphate levels to the normal range.
Simultaneous reduction in GFR and plasma phosphate concentrations. Three patients were studied before and after an 8-10 hr period of hemodialysis with a twin-coil dialyzer. In each patient the initial (i.e. predialysis) glomerular filtration rate was below 4 ml/min. GFR fell by an average of over 50% after dialysis, and plasma phosphate concentrations were reduced from a mean of 11.7 mg/100 ml to 3.6 mg/100 ml.
Parathyroid hormone (PTH) infusion. In many studies, under most of the foregoing conditions, after three or more clearance periods had been obtained, parathyroid hormone was administered intravenously. 250 U of PTH were infused over a 5-10 min interval after which 1 U/ 1 Basaljel, Wyeth Laboratories, Marietta, Pa. min was delivered by continuous infusion throughout the remainder of the study. A period of 45-60 min was allowed for equilibration after the priming injection of PTH, and then three or more additional clearance periods were obtained.
Glomerular filtration rate was measured by inulin clearance. Corrections were made for inuloid blank in blood and urine. Urine was collected through an indwelling bladder catheter, and at the end of each collection the bladder was washed with distilled water and air. Rigorous asepsis was used in performing the catheterizations; bacitracin-neomycin ointment was used as the catheter lubricant, and at the end of each study the bladder was irrigated with 200 ml of 1% neomycin solution. A urine culture was obtained at the end of each study and repeated 34 days later. None of the patients developed a urinary tract infection. Individual clearance periods varied from 20 to 30 min in duration, and blood was collected at the midpoint of each clearance period through an indwelling venous catheter.
Inulin was measured according to the method of Roe, Epstein, and Goldstein (2), phosphate by the method of Gomori (3) , and calcium with a Perkin-Elmer atomic absorption spectrophotometer. Additional details of the experimental procedures employed have been described (4) . TRP, the conventional expression for the apparent fractional reabsorption of phosphate, has been employed in describing the experimental results: (TRP = (1 -Cpo/ GFR) X 100, where Cpo4 = phosphate clearance). The fraction of filtered phosphate excreted (Cpo4/GFR X 100) also has been used. min, the phosphate excretion rates were virtually the same in all patients. The values for TRP in these patients are included in Fig. 3 . As in Fig. 1 , the lower the GFR, the lower the TRP. Thus, the ability to maintain constant phosphate excretion rates with decreasing levels of GFR (and presumably a decreasing population of functioning nephrons) was facilitated by the progressive reduction in the fraction of filtered phosphate reabsorbed. In the two patients with the lowest glomerular filtration rates (8 and 3 ml/min), plasma phosphate concentrations were elevated, and the increase in filtered phosphate also may be assumed to have contributed to the sustained phosphaturia (per nephron).
In order to study the importance of hyperphosphatemia in the progressive reduction of TRP that occurs with advancing nephron destruction, studies were performed in five patients before and after plasma phosphate concentrations were reduced from high to subnormal levels by the administration of aluminum carbonate gel. These data are shown in Table I (initial mean value 11.7 mg/100 ml; postdialysis value 3.6 mg/100 ml). The plasma calcium concentrations increased only slightly from 7.7 to 8.5 mg/100 ml. Despite the reduction in both determinants of the filtered load of phosphate (GFR and plasma phosphate concentrations), TRP rose only from a mean of 14.3 to 26.7%o. Table III . Whereas administration of PTH had virtually no effect in patients with hypocalcemia and hyperphosphatemia (Table I) and had only a very slight effect in patients with hypocalcemia and hypophosphatemia (Table  II) , a somewhat more marked influence was observed in the normocalcemic hypophosphatemic patients. Thus, the average value for TRP decreased from a mean of 86% before the adminis- See Table I for explanation of abbreviations. We believe that the data are best explained by invoking a key role of parathyroid hormone in the control of phosphate excretion in advancing renal disease. PTH levels are known to be increased in uremia (6, 7) . When plasma calcium concentrations were raised to a normal range and presumably PTH excretion was suppressed as a consequence, TRP levels rose strikingly.3 This increase occurred at-subnormal plasma phosphate concentrations, but it persisted when plasma phosphate concentrations were increased to normal levels. The fact that it required up to 2-3 wk of normocalcemia to reverse the depression of TRP may explain why previous efforts to accomplish this reversal with short-term calcium infusions in uremic subjects have not proven universally successful (8) (9) (10) .
If parathyroid hormone does play a principal role in the progressive modification of the phosphate excretory profile as renal disease advances, a 3 During the course of these studies four uremic patients were encountered in whom TRP values did not increase appreciably in response to correction of hypocalcemia for'up to 2 -months. In each there was'evidence of severe bone disease. Subtotal parathyroidectomy was performed in all. In three of the patients, TRP levels increased to over 80% postoperatively after vitamin D and calcium therapy. In the fourth patient, TRP remained low, but only two glands were found at surgery, and there is evidence of continuing osteitis fibrosa in this individual. These patients' will be described in detail separately.
Two garding assigning a primary role in the maintenance of phosphate homeostasis to parathyroid hormone is that the key biologic role of PTH presumably relates to the control of bone and calcium metabolism. If in advancing renal disease transient increases in phosphate concentrations occurring during periods of nephron destruction indirectly determine the rate of PTH secretion (via secondary changes in calcium concentrations) the economy of bones would become subservient to the excretion of phosphate by the kidney. A final question relates to the reasons for the delay in the restoration of TRP levels to normal after the induction of normocalcemia. If the biologic half-life of parathyroid hormone is normal in uremia it is conceivable that many patients with far advanced renal disease and hyperparathyroidism of long duration have some degree of autonomy of parathyroid function, and that suppression of hormone release requires sustained correction of hypocalcemia. It seems quite likely that the solution of these problems will require serial longitudinal measurements of the patterns of renal excretion of phosphate together with measurements of PTH activity, calcium and phosphate balance and plasma concentrations, and possibly other parameters such as magnesium balance and thyrocalcitonin levels as the nephron population is decreased in successive steps in regulated manner in the experi-'mental animal.
